Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

NYSEHealthcareMedical - Instruments & Supplies
最新資料
US$24.35
+US$0.45 · +1.88%
前收盤價
US$24.35
+US$0.45 · +1.88%
盤中時間採用ET。市場資料可能有所延遲。
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
日內區間
目前US$24.35
52週區間
目前US$24.35
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 112.44億 USD | 106.36億 USD | 103.6億 USD | 100.57億 USD | 121.46億 USD |
| 銷貨成本 | 78.65億 USD | 66.52億 USD | 62.1億 USD | 65.08億 USD | 74.26億 USD |
| 毛利 | 33.79億 USD | 39.84億 USD | 41.5億 USD | 35.49億 USD | 47.2億 USD |
| 研究與開發 | 5.18億 USD | 5.9億 USD | 5.18億 USD | 4.5億 USD | 5.31億 USD |
| 銷售、一般及管理費用 | 28.9億 USD | 29.67億 USD | 29.53億 USD | 30.97億 USD | 28.45億 USD |
| 營業費用 | 36.87億 USD | 39.7億 USD | 34.43億 USD | 63.94億 USD | 33.7億 USD |
| 利息收入 | 5200萬 USD | 6700萬 USD | 6900萬 USD | 1900萬 USD | 1400萬 USD |
| 利息支出 | 2.9億 USD | 4.08億 USD | 5.08億 USD | 4.13億 USD | 2.07億 USD |
| 折舊和攤銷 | 9.81億 USD | 9.97億 USD | 9.84億 USD | 10.72億 USD | 8.67億 USD |
| 營業利益 | −3.08億 USD | 1400萬 USD | 7.07億 USD | −28.45億 USD | 13.5億 USD |
| 淨利 | −9.57億 USD | −6.49億 USD | 26.56億 USD | −24.33億 USD | 12.84億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$23.60
下跌空間 3.08%年度分割調整後的每股現金分配。
US$0.52
2025年(完整年度)-52.1% 自從 2021
2026年(部分年度):US$0.03
US$1.085
2,021
US$1.15
2,022
US$1.16
2,023
US$1.04
2,024
US$0.52
2,025
US$0.03
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年8月28日 | US$0.01Quarterly | 2026年8月28日 | 2026年10月1日 |
股息 | 2026年5月29日 | US$0.01Quarterly | 2026年5月29日 | 2026年7月1日 |
股息 | 2026年2月27日 | US$0.01Quarterly | 2026年2月27日 | 2026年4月1日 |
股息 | 2025年11月28日 | US$0.01Quarterly | 2025年11月28日 | 2026年1月2日 |
股息 | 2025年8月29日 | US$0.17Quarterly | 2025年8月29日 | 2025年10月1日 |
股息 | 2025年5月30日 | US$0.17Quarterly | 2025年5月30日 | 2025年7月1日 |
除息 2026年8月28日
US$0.01
Quarterly
2026年8月28日登記 · 支付日 2026年10月1日
除息 2026年5月29日
US$0.01
Quarterly
2026年5月29日登記 · 支付日 2026年7月1日
除息 2026年2月27日
US$0.01
Quarterly
2026年2月27日登記 · 支付日 2026年4月1日
除息 2025年11月28日
US$0.01
Quarterly
2025年11月28日登記 · 支付日 2026年1月2日
除息 2025年8月29日
US$0.17
Quarterly
2025年8月29日登記 · 支付日 2025年10月1日
除息 2025年5月30日
US$0.17
Quarterly
2025年5月30日登記 · 支付日 2025年7月1日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T240.29億0.02%129.35兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI4.27億0.02%2.3兆 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO3.57億0.02%1.8兆 USD0.03%US$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB3.09億0.16%1853億 USD0.03%US$289.48+0.64%
Invesco S&P 500 Equal Weight ETFRSP1.96億0.20%977.83億 USD0.20%US$213.04+0.55%
Vanguard Morningstar Small-Cap Value ETFVBR1.77億0.26%682億 USD0.05%US$234.43+0.22%
iShares Core S&P 500 ETFIVV1.64億0.02%8964.4億 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY1.52億0.02%8172億 USD0.09%US$778.57+0.60%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Small-Cap ETFVB
Invesco S&P 500 Equal Weight ETFRSP
Vanguard Morningstar Small-Cap Value ETFVBR
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPYAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。